Antithrombotic Activity of Dermatan Sulphates, Heparins and their Combination in an Animal Model of Arterial Thrombosis

Summary

Dermatan sulphates have been shown to inhibit thrombus formation and thrombus growth in different experimental models of venous thrombosis. At variance with heparins, they show a remarkably low haemorrhagic potential. On the other hand, very few data are available on the effect of dermatan sulphates on arterial thrombus formation. We evaluated the effects of a low molecular weight (LMW)-dermatan sulphate, a high molecular weight (HMW)-dermatan sulphate and sulo-dexide (a mixture of fast-moving heparin fraction and dermatan sulphate) in comparison with LMW- and HMW-heparin, in a model of arterial thrombosis in rats. The insertion of an artificial prosthesis into the abdominal aorta of the animals induced the formation of an occluding thrombus within 2-5 days. The time in which 50% of the loops became occluded (OT₅₀) was also calculated and used to compare the efficacy of the different drug treatments. This was 2.84 days for control animals and 4.25 and 5.80 days for HMW- and LMW-dermatan sulphate, respectively. Neither drug changed the “template” bleeding time, even at higher doses. In contrast, HMW-heparin at doses (8 mg/kg, sc, twice a day) inducing an antithrombotic activity comparable to that of dermatan sulphates, dramatically prolonged the bleeding time. LMW-heparin at the same doses was ineffective. Sulodexide (10 mg/Kg, sc, twice a day) prolonged the occlusion time to the same extent as HMW-heparin (OT₅₀ 5.10 vs. 4.14 days), with less an effect on the bleeding time (144 ± 6 s vs. >300 s, respectively). Histological examination confirms that the prolongation of occlusion time induced by the drugs is really related to thrombus formation inhibition at the site of arterial wall injury.

Acetyl salicylic acid (ASA) (100 mg/kg/day in drinking water as lysine acetylsalicylate) did not modify the effect of Desmin 370 and Sulodexide on both occlusion and bleeding time. However, while it did not increase the antithrombotic activity of HMW-heparin, it significantly prolonged its haemorrhagic effect. In conclusion, dermatan sulphates are effective inhibitors of arterial thrombosis in rats, without inducing bleeding complications.

• References

• 1 Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulphate. J Biol Chem 1983; 258: 6713-6716
• 2 Fernandez F, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. The haemor-rhagic and antithrombotic effects of dermatan sulphate. Br J Haematol 1986; 64: 309-317
• 3 Merton RE, Thomas DP. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents. Thromb Haemost 1987; 58: 839-842
• 4 Maggi A, Abbadini M, Pagella PG, Borowska A, Pangrazzi J, Donati MB. Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model. Haemostasis 1987; 17: 329-335
• 5 Barbanti M, Calanni F, Babbini M, Bergonzini G, Parma B, Marchi E. Antithrombotic activity of Desmin 370. Comparison with a high molecular weight dermatan sulphate. Thromb Res 1993; 71: 417-422
• 6 Barbanti M, Calanni F, Milani MR, Marchi E, Semeraro N, Colucci M. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis; evidence for an anticoagulant – independent mechanism. Thromb Haemost 1993; 69: 147-151
• 7 Van Ryn-McKenna J, Ofosu FA, Gray E, Hirsh J, Buchanan MR. Effects of dermatan sulphate and heparin on inhibition of thrombus growth in vivo. Ann NY Acad Sci 1989; 556: 304-312
• 8 Hoppensteadt D, Racanelli A, Walenga JM, Fareed J. Comparative antithrombotic and hemorrhagic effects of dermatan sulphate, heparan sulphate and heparin. Semin Thromb Hemost 1989; 15: 378-385
• 9 Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. New Engl J Med 1988; 318: 1162-1173
• 10 Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71
• 11 Abbadini M, Jin Zhu G, Maggi A, Pangrazzi J, Donati MB, Mussoni L. Dermatan sulphate induces plasminogen activator release in the perfused rat hindquarters. Blood 1987; 70: 1858-1860
• 12 Marsh NA. Does heparin stimulate fibrinolysis. Br J Haematol 1990; 76: 163-167
• 13 Dol F, Petitou M, Lormeau J-C, Choayz J, Caranobe C, Sié P, Saivin S, Houin G, Boneu B. Pharmacologic properties of a low molecular weight dermatan sulphate: Comparison with unfractionated dermatan sulphate. J Lab Clin Med 1990; 115: 43-51
• 14 Bergonzini GL, Bianchini P, Hoppensteadt D, Parma B, Osima B, Walenga JM, Fareed J. Pharmacokinetics of native and low molecular weight dermatans: preliminary studies in rats and primates. Semin Thromb Hemost 1991; 17 Suppl (Suppl. 02) 235-239
• 15 Carrie D, Caranobe C, Gabaig AM, Larroche M, Boneu B. Effects of heparin, dermatan sulphate and of their association on the inhibition of venous thrombosis growth in the rabbit. Thromb Haemost 1992; 68: 637-641
• 16 Cadroy Y, Dol F, Caranobe C, Petitou M, Lormeau JC, Sié P, Choay J, Boneu B. Standard heparin enhances the antithrombotic activity of dermatan sulphate in the rabbit but CY 216 does not. Thromb Haemost 1988; 59: 295-298
• 17 Radhakrishnamurthy B, Sharmay C, Bhandaru RR, Berenson GS, Stanzani L, Mastacchi R. Studies of chemical and biologic properties of a fraction of sulodexide, a heparin-like glycosaminoglycan. Atherosclerosis 1986; 60: 141-149
• 18 Reyers I, Mysliwiec M, Mussoni L, Donati MB. Stasis-induced venous thrombosis. In: Angiological Symposium Kitzbuhehel. Standardization of Animal models of thrombosis Breddin K, Zimmerman R. eds. Schattauer; Stuttgart: 1983. 17 99-104
• 19 Homstra G, Vendelmans-Starrenburg A. Induction of experimental arterial occlusive thrombi in rats. Atherosclerosis 1973; 17: 369-382
• 20 Dejana E, Villa S, de Gaetano G. Bleeding time in rats: a comparison of different experimental conditions. Thromb Haemost 1982; 48: 108-111
• 21 Barbanti M, Calanni F, Marchi E, Semeraro N, Colucci M. Desmin 370, a low molecular weight dermatan sulphate, reduces the weight of preformed thrombi in rats made afibrinogenemic by ancrod. Thromb Haemost 1995; 73: 287-290
• 22 Buchanan MR, Boneu B, Ofosu F, Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood 1985; 65: 198-201
• 23 Palm M, Mattsson C, Svahn CM, Weber M. Bleeding times in rats treated with heparin, heparin fragments of high and low anticoagulant activity and chemically modified heparin fragments of low anticoagulant activity. Thromb Haemost 1990; 64: 127-132
• 24 Casu B, Naggi A, Oreste P, Torri G, Pangrazzi I, Maggi A, Abbadini M, Donati MB. Bleeding associated with heparin contaminants. Lancet 1987; 1: 1088
• 25 Heinrich D, Gorg M, Schulz M. Effects of unfractionated and fractionated heparin on platelet function. Haemost 1988; 18 suppl (Suppl. 03) 48-54
• 26 Sié P, Fernandez F, Caranoble C, Gabaig AM, Boneu B. Inhibition of thrombin-induced platelet aggregation and serotonin release by antithrombin III and heparin cofactor II in the presence of standard heparin, dermatan sulphate and pentosan polysulfate. Thromb Res 1984; 35: 231-236
• 27 Ofosu FA, Gray E. Mechanisms of action of heparin: applications to the development of derivatives of heparin and heparinoids with antithrombotic properties. Semin Thromb Hemost 1988; 14: 9-17
• 28 Bendayan P, Boccalon H, Dopuoy D, Boneu B. Dermatan Sulphate is a more potent inhibitor of clot-bound thombin than unfractionated and low molecular weight heparins. Thromb Haemost 1994; 71: 576-580
• 29 Thomas DP, Gray E, Merton RE. Potentiation of the antithrombotic action of dermatan sulphate by small amounts of heparin. Thromb Haemost 1990; 64: 290-293
• 30 Okwusidi JI, Anvari N, Kulczycky M, Blajchman MA, Buchanan MR, Ofosu FA. Fibrin moderates the catalytic action of heparin but not that of dematan sulphate on thrombin inhibition in human plasma. J Lab Clin Med 1991; 117: 359-364
• 31 Buchanan MR, Liao P, Ofosu FA. Simultaneous inhibition of thrombin by ATIII and HCII and prevention of thrombus formation and growth: relative effects of heparin and sulodexide. Thromb Res 1994; 74: 463-475
• 32 Barbanti M, Guizzardi S, Calanni F, Marchi E, Babbini M. Antithrombotic and thrombolytic activity of sulodexide in rats. Int J Clin Lab Res 1992; 22: 179-184
• 33 Reyers I, Mussoni L, Donati MB, de Gaetano G. Severe thrombocytopenia delays but does not prevent the occlusion of an arterial prosthesis in rats. Thromb Haemost 1981; 46: 558-560
• 34 Reyers I, Hennissen A, Donati MB, Homstra G, de Gaetano G. Aspirin and the prevention of experimental arterial thrombosis: difficulty in establishing unequivocal effectiveness. Thromb Haemost 1985; 54: 619-621
• 35 Reyers I, Donati MB, de Gaetano G. Warfarin anticoagulation prevents experimental arterial thrombosis in rats without inducing haemorrhage. Thromb Res 1983; 29: 465-468